Chairman Patrick Walsh, a distinguished figure in the CDMO sector and Operating Partner at Ampersand Capital Partners, steps in as the new Executive Chairman of MedPharm Ltd. The board also welcomes Minor Hinson, representing Bourne Partners Strategic Capital, as a new member. These appointments underscore MedPharm’s commitment to steering the company into its next growth […]

Board Member David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, […]

Board Member Minor Hinson is a Senior Managing Director and the Chief Investment Officer of Bourne Partners Strategic Capital (“BPSC”). Over the course of his career, Minor has been involved in financial transactions totaling over $10 billion, including venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock […]

Board Member Eric has over 25 years of financial leadership experience in the pharmaceutical industry, the last 17 years in pharmaceutical contract developing and manufacturing. Most recently he was CFO of Alcami Corporation, retiring after the successful sale of that company. He was also CFO and co-founder of TriPharm Services. Previously, Eric was CFO of […]

Board Member Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the […]